The mechanism of degradation of mutant insulin receptors.

突变胰岛素受体的降解机制。

• 批准号: 07457221
• 负责人: KOBAYASHI Masashi
• 金额: $ 3.26万
• 依托单位: TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07457221/
• 关键词: Malecular chaperones; Insulin receptor Disease; Insulin Resistance

We indentified two novel heterozygous missense mutations of the insulin receptor gene : the Asp 1179 mutation in one family and the Leu 1193 mutation in two unrelated families with extreme insulin resistance. In these patients, the number of insulin receptors on the cell surfacc was found to be markedly decreased by insulin binding and surface labeling studies in transformedlymphocytes. Insulin binding to the transfected COS 7 cells and Rat-1 cells with both mutant cDNAs was also decreased to 5-31% of normal, and the mutant insulin receptors showed a markedly decreased tyrosine kinase activity. Although biosynthetic labeling studies revealed the both mutant receptors were synthesized as 190-kDa proreceptors, the degradation rate of the mutant proreccptors ws 2-fold faster than that of the wild type proreceptors. Interestingly, two molecular chaperones, Hsc 70 and Hsp 90 bound with high affinity to these abnormal insulin receptor precursors in cells and intracellular beta-subunit GST-fusion proteins with these mutations. Furthermore, microinjection of anti-Hsp 90 antibody prevented the degradation of these mutant insulin proreceptors and recruited them to the cell surface. These results suggest that Asp 1179 an Leu 1193 mutations in the insulin receptor kinase domain are unique in causing decreased insulin receptor number on the cell surface and that molecular chaperons play an important role for the accelerated intracellular degradation of these mutant insulin receptors.

我们鉴定了两个家族中的胰岛素受体基因的两个新型杂合错义突变：ASP 1179突变，LEU 1193突变在两个具有极端胰岛素耐药性的无关家族中。在这些患者中，发现细胞表面上的胰岛素受体的数量通过胰岛素结合和表面标记研究显着减少。胰岛素与转染的COS 7细胞和与两个突变cDNA的大鼠1细胞的结合也降低到正常的5-31％，突变胰岛素受体显示出明显降低的酪氨酸激酶活性。尽管生物合成标记研究表明，两个突变受体都是合成的，为190 kDa的受体受体，但突变体prorecctors WS的降解速率比野生型前体的降解速度快2倍。有趣的是，两个分子伴侣HSC 70和HSP 90与这些异常胰岛素受体前体和细胞内β-亚基GST融合蛋白具有高亲和力结合，并具有这些突变。此外，抗HSP 90抗体的显微注射阻止了这些突变胰岛素前受体的降解，并将其募集到细胞表面。这些结果表明，ASP 1179胰岛素受体激酶结构域中的LEU 1193突变在导致细胞表面的胰岛素受体数量降低方面是独一无二的，并且分子伴侣在这些突变胰岛素受体的加速内降解中起着重要作用。

项目成果

T. Sasaoka, ....M. Kobayashi: "Comparison of the insulin and insulin-like growth factor-1 mitogenic intracellular signaling pathways" Endocrinology. 137. 4427-4434 (1996)

T.笹冈，....M。

T.Sasaoka・・・・M.Kobayashi.: "Fundional importance of amino-terminal domain of shefor interaction with insulin and epidermal growth factor receptors・・・・・" J.Biol Chem. 271. 20082-20087 (1996)

T.Sasaoka・・・・M.Kobayashi.：“she 的氨基末端结构域对于与胰岛素和表皮生长因子受体相互作用的基本重要性...”J.Biol Chem. 271. 20082-20087 (1996)

Y. Takata, ....M. Kobayashi: "Pioglitazone attenuates the inhibitory effect phorbolester on epidermal growth factor receptor autophosphorylation." Biochem Biophys Acta. 1312. 68-72 (1996)

Y.高田，....M。

T.Haruta: "Amplification and analysis of promotor region of insulin receptor gene in a patient with severe insulin resistance." Metabolism. 44. 430-437 (1995)

T.Haruta：“严重胰岛素抵抗患者胰岛素受体基因启动子区的扩增和分析。”

Haruta T.: "Amplification and analysis of promoter region of insulin receptor gene in a patient with severe insulin resistance." Metabolism.

Haruta T.：“严重胰岛素抵抗患者胰岛素受体基因启动子区域的扩增和分析。”